Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by stockpatrolon Nov 29, 2022 5:29pm

183 Views

Post# 35137991

AGN.c is currently two weeks into Phase 1 clinical trials fo

AGN.c is currently two weeks into Phase 1 clinical trials for DMT treatment of stroke.

https://twitter.com/top_prospector/status/1597292188987453440

Phase 1's object is to dentify the safety, tolerability, and pharmacokinetics of DMT administered as an intravenous followed by prolonged infusion, testing durations that have yet to be studied.

Several Phase 1 studies have been succesfully conducted on DMT, AGN.c is not expecting any safety issues from Phase 1, the resulting data will help them plan Phase 2 more effectively.

<< Previous

Bullboard Posts

Next >>

Critical materials crisis: Diversifying away from China’s monopoly